Liver cirrhosis is the final stage of chronic damage with the formation of regeneration and fibrosis nodes that disrupt the architecture and function of the organ.
Liver fibrosis is an excessive accumulation of connective tissue (replacement with fibrous tissue) that accompanies chronic hepatitis, alcoholic damage, autoimmune processes.
Liver amyloidosis is the deposition of pathological amyloid protein in liver tissues, which causes organ enlargement, dysfunction, and portal hypertension.
HepaCELLNESS® is a cellular liver tissue restoration program that combines intravenous therapy, local cell administration, immunomodulation, and antifibrotic action to stop liver destruction and restore its function.
The liver performs a number of important functions: it participates in hematopoiesis (depositing blood and destroying red blood cells), metabolism (in particular, it is the main organ for the synthesis of most plasma proteins – building materials for the entire body), detoxification (removal of harmful substances that come with food or are formed as a result of the work of intestinal microflora), and digestion. Therefore, it is not surprising that disruption of its work affects the state of other body systems.
Causes and symptoms of liver diseases (cirrhosis, fibrosis, amyloidosis)
Among the main causes of acquired liver diseases are viral infections (hepatitis, cytomegalovirus), exposure to toxic substances, alcohol abuse and malnutrition.
Liver fibrosis is an excessive accumulation of connective (fibrous) tissue, which replaces liver tissue and leads to impaired function. Fibrosis accompanies chronic hepatitis, alcohol damage, autoimmune processes.
Liver amyloidosis is the deposition of the pathological protein amyloid in liver tissues, which causes organ enlargement, impaired function and portal hypertension.
The final stage of chronic liver damage is cirrhosis with the formation of regeneration and fibrosis nodes, which change the structure and function of the organ.
As a rule, the primary signs of liver cirrhosis appear when the disease has been ongoing for a long time and is in an advanced state. Symptoms of cirrhosis, amyloidosis and other liver diseases:
- yellowing of the skin and whites of the eyes, itching;
- the appearance of rashes and spots on the skin;
- constant fatigue, weakness;
- a feeling of heaviness, pain in the right hypochondrium;
- an enlarged abdomen, swelling of the legs;
- appetite disturbances, nausea, weight loss;
- changes in consciousness, forgetfulness (signs of encephalopathy).
Cirrhosis, fibrosis and amyloidosis lead to portal hypertension, ascites (excessive accumulation of fluid in the abdominal cavity), liver failure, increase the risk of hepatic encephalopathy and hepatocellular carcinoma and ultimately become life-threatening if not treated.
Indications for cell therapy in liver diseases
Cell therapy is indicated for all of the liver diseases listed above. Moreover, it can give good results even in cirrhosis of the liver in the last fourth stage, improving the patient’s condition and starting regeneration processes.
Advantages of cell therapy in cirrhosis, fibrosis and amyloidosis of the liver
The cellular program for liver tissue restoration HepaCELLNESS® combines intravenous therapy, local cell administration, immunomodulation and antifibrotic action in order to stop liver destruction and restore its functions. The advantages of cell therapy in the treatment of fibrosis, amyloidosis and liver cirrhosis are as follows:
- complex treatment: cell therapy, preparation, dynamic control;
- effect on fibrosis, hepatocyte regeneration, immunomodulation;
- individual approach and support from a Smart Cell doctor.
Cell therapy helps stop the progression of cirrhosis and other liver diseases and improve the patient’s quality of life.
Mechanism of action of cell therapy on liver tissue
Cell therapy affects both liver diseases themselves and their complications. The mechanism of action of HepaCELLNESS® is based on the following principles:
- antifibrotic effect – MSCs inhibit the activity of stellate cells responsible for fibrosis;
- hepatocyte regeneration – stimulate the division and renewal of functional liver cells;
- immunomodulation – reduction of autoimmune and chronic inflammation;
- angiogenesis – improvement of microcirculation in liver tissues;
- support of metabolic function – improvement of protein, enzyme, hormone synthesis.
In addition, cell therapy helps with the following complications of cirrhosis, fibrosis and amyloidosis:
- ascites, portal hypertension – MSCs stabilize liver function, improve blood circulation in the portal system;
- hepatic encephalopathy – reduction of toxic load due to hepatocyte restoration;
- jaundice syndrome, itching of the skin – improvement of bile secretion;
- risk of liver failure – stabilization of protein synthesis functions, clotting factors;
- slowing down the progression to carcinoma – reduction of chronic inflammation and fibrosis.
Cell therapy works with the causes of the disease, which affects the manifestations of liver cirrhosis, including improving the patient’s appearance.
Results of cell therapy in liver diseases
Cell therapy stops liver fibrosis and starts the regeneration process, because the liver is a unique organ that is able to restore its own damaged tissues, even after 70% is removed. VIRTUS patients record the following results of cell therapy in cirrhosis, fibrosis and amyloidosis:
- improved general well-being, energy;
- reduced manifestations of liver failure;
- reduced ascites volume, improved appetite;
- improved laboratory parameters: bilirubin, transaminases, albumin;
- slowed progression to cirrhosis or carcinoma;
- improved quality of life.
After treatment, patients, including those who applied in a serious condition, achieve stable remission and have no external signs of the disease.